正如DeepSeek以精简预算创造AI突破,中国生物科技公司也凭借高素质、低成本的人才优势,展现出更快的创新速度和更高的研发效率。四年间,中国在全球大型医药交易占比从5%跃升至30%。从研发创新到国际并购,中国创新药企正在重塑全球医药创新版图。近期,中国AI企业DeepSeek的突破性进展引发全球关注。德意志银行2月5日发布报告指出,不只是deepseek,从服装、钢铁、造船到电信设备,再到最新的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.